SOURCE: CymaBay Therapeutics

CymaBay Therapeutics Logo

June 02, 2014 09:00 ET

CymaBay Therapeutics to Present at Upcoming Conferences

NEWARK, CA--(Marketwired - June 02, 2014) - CymaBay Therapeutics, Inc. (OTCQB: CYMA), today announced that senior management will present an overview of the company at the following upcoming conferences.

Jefferies 2014 Global Healthcare Conference
Date: June 5, 2014
Location: Grand Hyatt New York
Presentation: 8:00am - 8:30am

2014 Wells Fargo Healthcare Conference
Date: June 18, 2014
Location: InterContinental Boston
Presentation: 1:50pm - 2:20pm

About CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies to treat metabolic and rare diseases with high unmet need. Arhalofenate, the Company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints through an anti-inflammatory effect while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the key debilitating symptom and the underlying cause of the disease. CymaBay is currently investigating arhalofenate in a 12-week Phase 2b clinical trial in patients with gout. The Company's second product candidate, MBX-8025, demonstrated favorable effects on cholesterol, triglycerides and markers of liver health in a Phase 2 clinical trial in patients with mixed dyslipidemia. MBX-8025 is currently being considered for further development in certain orphan diseases.
For additional information about CymaBay visit www.cymabay.com.

Contact Information